Lotus Pharmaceutical (1795 TT): Continued Stellar Growth in Q2; Pipeline Expansion to Drive Growth
​Lotus saw 53% YoY revenue growth in 2Q23, driven Lenalidomide and Suboxone in the US and branded products in Taiwan. EPS exceeded expectations....
516 Views
CSL Ltd (CSL AU): FY23 Guidance Cut Drags Near-Term Prospect; Long-Term Growth Drivers Still Intact
CSL reduced FY23 profit projection due to higher-than-anticipated Fx headwind of $230–250M from $175M. Strong demand for existing products and new...
501 Views
U. S. Equity Strategy: Small-Caps Closing the Gap
Major averages in the US (S&P 500, Dow, Russell 2000) and Europe (STOXX 600 & 50) each had throwbacks to their prior breakout levels last...
518 Views
Amarin--Our Talks With The CEO & An Update on New Trial Data Released at ACC Conference
Strong Q1 to Come: We recently had a call with Amarin's CEO, John Thero, and update our model with quarterly estimates. Q1 should see revenue...
2.7k Views
Amarin Q4 2018 Conference Call--Strong Sales & High Confidence
Q4 2018 Revenues Stronger Than Pre-Announcement on January 4th: Amarin released its Q4 2018 results today and held a conference call. Results of...
773 Views